In a study of mice, researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new approach that combines an anti-psychotic drug, a statin used to lower high cholesterol levels, and radiation to improve the overall survival in mice with glioblastoma. Glioblastoma is one of the deadliest and most difficult-to-treat brain tumors. Researchers found the triple combination extended the median survival 4-fold compared to radiation alone.
Radiation therapy is part of the standard-of-care treatment regimen for glioblastoma, often helping prolong the survival of patients. However, survival times have not improved significantly over the past two decades and attempts to improve the efficacy of radiotherapy through the use of pharmaceuticals have been hampered by the normal tissue toxicity of the drugs and the inability to penetrate the blood-brain barrier.
UCLA researchers previously reported that the first-generation dopamine receptor antagonist trifluoperazine in combination with radiation prolonged survival in mouse models of glioblastoma, but ultimately, the mice become resistant to the therapy. To help overcome this resistance, the team used quetiapine, a second-generation dopamine receptor antagonist, which not only enhanced the efficacy of radiotherapy in glioblastoma but also generated a metabolic vulnerability in the lipid homeostasis. The discovery that the combination induced the cholesterol biosynthesis pathway allowed the team to target this process with statins.
The team tested the approach using patient-derived glioblastoma lines provided by the Biospecimen and Pathology Core of the UCLA SPORE in Brain Cancer. Quetiapine was identified in a screen of dopamine receptor antagonists for their ability to prevent phenotype conversion of non-tumorigenic glioblastoma cells into radiation-induced glioma initiating cells. Atorvastatin (Lipitor) was selected because of its known ability to cross the blood-brain-barrier.
While radiation alone prolongs survival of glioblastoma to some extent, attempts to enhance the treatment have not been successful. The results of the study provide evidence that using a dopamine receptor antagonist in combination with Atorvastatin and radiation may help extend the survival for people with glioblastoma. The combination therapy also includes FDA-approved drugs that can rapidly be translated into a clinical trial.
The senior author Dr. Frank Pajonk, is a professor of Radiation Oncology at the David Geffen School of Medicine at UCLA and a member of the Jonsson Cancer Center. The lead author is Dr. Kruttika Bhat, a project scientist in Pajonk's laboratory. Other authors are Mohammad Saki, Fei Cheng, Ling He, Dr. Le Zhang, Angeliki Ioannidis, David Nathanson, Jonathan Tsang, Steven Bensinger, Dr. Phioang Leia Nghiemphu, Dr. Timothy Cloughesy, Dr. Linda Liau and Dr. Harley Kornblum, all of UCLA.
The study was published online in the Journal of the National Cancer Institute.
The work was funded in part by the National Cancer Institute and the National Institutes of Health's Brain Specialized Programs of Research Excellence, or SPORE, at UCLA, which helps advance work in the prevention, detection and treatment of brain tumors.
Learn more about myUCLAhealth